An FDA-approved compound library of 1,448 drugs was purchased from Selleck Chemicals. c-MET inhibitor INC280 was supplied from Novartis (Basel, Switzerland). HAP1, HAP1 RNF43 KO, and HAP1 PWWP2B KO cells were seeded at a density of 2,000 or 3,000 cells per well in 384-well, clear-bottom culture plates with 20 µL IMDM or RPMI 1640 medium containing 10% FBS for 24 h. Then, 10 μM of FDA-approved drug was added to the wells, and the cells were incubated for an additional 48 h. Control cells were not exposed to drugs. On the day of the proliferation assay, the medium was removed, 20 μL of fresh medium was added to each well of the 384-well plates, followed by 5 μL of MTS solution (Cell Titer 96 Aqueous One Solution Cell Proliferation Assay Kit; Promega, Madison, WI, USA), and the plates were incubated at 37 °C for 4 h in a humidified environment with 5% CO2. The absorbance was read at 490 nm using a PerkinElmer (Waltham, MA, USA) EnVision luminescence microplate reader. Data were validated using the Zʹ factor analysis. The percentage inhibition was expressed as [viability level of test samples/viability level of control)] × 100.
Envision luminescence microplate reader
Manufactured by PerkinElmer
Sourced in United States
The EnVision luminescence microplate reader is a high-performance multi-mode microplate reader designed for a wide range of detection modes, including luminescence, fluorescence, and absorbance. The instrument is capable of rapidly and accurately measuring multiple samples simultaneously in a microplate format.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using envision luminescence microplate reader
1
High-throughput Screening of FDA-approved Drugs
2
High-throughput Screening of FDA-approved Drugs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
An FDA-approved compound library of 1,448 drugs was purchased from Selleck Chemicals. INC280 was supplied from Novartis (Basel, Switzerland). HAP1, HAP1 RNF43 KO and HAP1 PWWP2B KO cells were seeded at a density of 2,000 or 3,000 cells per well in 384-well, clear-bottom culture plates with 20 µL IMDM or RPMI 1640 medium containing 10% FBS for 24 h. Then, 10 µM of FDA-approved drug was added to the wells, and the cells were incubated for an additional 48 h. Control cells were not exposed to drugs. On the day of the proliferation assay, the medium was removed, 20 µL of fresh medium was added to each well of the 384-well plates, followed by 5 µL of MTS solution (Cell Titer 96 Aqueous One Solution Cell Proliferation Assay Kit; Promega, Madison, WI, USA), and the plates were incubated at 37°C for 1 h in a humidi ed environment with 5% CO 2 . The absorbance was read at 490 nm using a PerkinElmer (Waltham, MA, USA) EnVision luminescence microplate reader. Data were validated using the Z factor analysis. The percentage inhibition was expressed as [viability level of test samples/viability level of control)] × 100.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!